Transcript
Capital One Bank Announcer (0:00)
With no fees or minimums on checking accounts, it's no wonder the Capital One bank guy is so passionate about banking with Capital One. If he were here, he wouldn't just tell you about no fees or minimums. He'd also talk about how most Capital One cafes are open seven days a week to assist with your banking needs. Yep, even on weekends it's pretty much all he talks about in a good way. What's in your wallet? Term supply see capitalone.com bank capital1na member FDIC.
T-Mobile/US Cellular Advertiser (0:30)
Everyone deserves to be connected. That's why T Mobile and US Cellular are joining forces. Switch to T Mobile and save up to 20% versus Verizon by getting built in benefits they leave out. Check the math@t mobile.com switch and now T mobile is in US cellular stores.
T-Mobile/US Cellular Plan Details Announcer (0:50)
Savings versus Comparable Verizon plans plus the cost of optional benefits plan features in Texas and fees vary. Savings with three plus lines include third line free via monthly bill credits Credit stop if you cancel any lines Qualifying credit required.
Dr. Ben Bickman (1:00)
Boost Mobile is now sending experts nationwide to deliver and set up customers new phones. Wait, we're going on tour? We're delivering and setting up customers phones? It's not a tour.
Skyrizi Advertisement Narrator (1:08)
Not with that attitude.
Dr. Ben Bickman (1:09)
Introducing store to door switch and get a new device with expert setup and delivery. Delivery available for select devices purchased@boostmobile.com. Welcome to the Metabolic Classroom Podcast. I'm Ben Bickman. Thanks for letting me be your guest professor for the next few minutes. Don't worry about any pop quizzes. I'm here to simply make the science of metabolism clear, practical and engaging. Welcome back to the metabolic classroom. I'm Dr. Ben Bickman, metabolic scientist and professor of Cell biology. In this mini lecture, I want to teach you about two molecular master switches that control how your cells age, grow and even survive. These two signals are AMPK and mtor and I guarantee that by the end of this episode you'll understand why these two pathways may hold the key to extending not just lifespan, but more importantly, I would say health span. These two pathways are essentially opposites. They are like a cellular seesaw. When one is up, the other is going to be down and the balance between them may determine whether your cells are building and growing or cleaning house and repairing. Even if you've heard about the so called longevity drug Rapamycin, or you've wondered why metformin keeps showing up in anti aging research, or even maybe you've heard me talk about all the benefits of ketones, all of these tie directly into AMPK and mtor But I want to be clear from the start, understanding these pathways doesn't mean we have a magic pill. In fact, as we'll discuss, the pharmaceutical approach to manipulating MTOR comes with some serious concerns. So let's break all of this down. Let's start with ampk. Speaking of breaking things down, AMPK stands for AMP activated protein kinase. Think of AMPK as your cells fuel gauge or some kind of energy sensor when cellular energy is low. And by that I mean ATP. So I mean ATP levels have dropped and AMP levels rise. AMP is a product of breaking down ATP. I know nowadays a lot of people use the term cellular energy mostly because it sounds so cool, but I'm using it very deliberately. I mean ATP, which is the actual molecule that the cell is breaking in order to get work done. So when ATP is low, or back to what I said previously, cellular energy is low, AMPK gets activated and it essentially sends a very clear message to the cell and all of its other metabolic machinery, which is we're running low on energy. It's time to stop building and start burning. When AMPK is activated, thus several critical things will happen. First, it stimulates catabolic processes, the pathways that break things down to generate ATP, like for example, fatty acid oxidation. Your cells will start burning more fat for fuel. Second, AMPK will inhibit anabolic processes, the energy consuming pathways that aren't immediately necessary for the survival of the cell. So things like building new proteins or making new fats. But here's where it gets really interesting for aging, AMPK also activates autophagy, the cellular housekeeping process, where your cells clean up damaged proteins and dysfunctional mitochondria. This is absolutely critical. As demonstrated in a really clever 2012 paper. AMPK controls autophagy through direct regulation of MTOR and another protein, ulk1 signaling, which augments the quality of what we might call cellular housekeeping. AMPK also improves the stress resistance within the cell through the activation of transcription factors like Fox O, NRF2 as well as SIRT1. SIRT1 is a big one when it comes to aging. It suppresses inflammation also through inhibition of NF Kappa B signaling. That's a protein that we've talked about quite a bit in the metabolic classrooms in the past. In essence, AMPK is your cellular guardian of longevity. And here's the problem. Emerging studies indicate that AMPK responsiveness clearly declines with aging as we get older. In other words, our cellular fuel gauge becomes less sensitive. This impairs the metabolic regulation, increases oxidative stress increase and reduces that critical Process of autophagy. Now let's get to the other side of what we could call the seesaw, which is mtor. MTOR stands for mechanistic target of rapamycin. If AMPK says it's time to burn or break things down and clean house, MTOR says it's time to build and clutter up the place with more molecules. MTOR is a serine threonine kinase and it integrates multiple signals from nutrients. So it can respond to nutrients when they come to a cell. Growth factors and energy status to control cell growth, things like protein synthesis, fat synthesis, like I mentioned, and even metabolism. It exists in two distinct complexes, mtorque. That's where the torque torc. Now mtorc1 and mtorque2. And again the C stands for complexes and mtorc1 and mtorc2. For our purposes today, I'm primarily focused on mtorc1, which is the nutrient sensing complex. When nutrients are abundant, particularly amino acids and glucose, MTORC1 is activated. It then promotes protein synthesis by phosphorylating or activating targets downstream, other downstream signals. The effects of that are, for example, one being that it can stimulate the synthesis of things like ribosomes and many, many other prot. But the ribosome being very important for the growth and proliferation or multiplication of the cell and importantly to bring back in an effect I mentioned a Moment ago, when MTORC1 is turned on, it inhibits or suppresses autophagy. And there is within this then some key insight for aging. When MTOR activity is balanced and appropriately regulated, cells can maintain normal glucose and lipid levels, they're sensitive to insulin, they have reduced stress and toxicity, and they have a balanced cell cycle. So they know when it's time to grow and when it's time not to. The result is improved overall health and prolonged lifespan. But when MTOR becomes hyperactive, and this happens with chronic nutrient excess, we see elevated glucose and lipid levels, we see insulin resistance, increased cellular stress and disrupted cell cycles. These disruptions directly contribute to metabolic diseases like diabetes and obesity. And as the theory goes, it accelerates aging. Now, it does go beyond theory, depending on the model, which I'll get to in a moment. But the takeaway here is that MTOR is essential for growth and repair, but chronically elevated MTOR activity is a likely driver of aging and age related disease, at least in non human models. And this brings us to rapamycin as a good example. And I want to address this head on, because there is a lot of Hype in the longevity space about this drug. Rapamycin specifically inhibits MTORC1. And the animal research is genuinely impressive. I won't dismiss that. But I am very skeptical about translating that research into and those findings to humans. And let me tell you why. First, let's acknowledge the animal data. In 2009, there was a very good paper published in Nature showing that rapamycin extends lifespan in mice even when it started later in life. Subsequent studies showed even larger effects at higher doses, with lifespan increasing up to 25% in some experiments. Those are significant findings in mice. But here's the critical point that often gets lost in the enthusiasm. We have no evidence that rapamycin extends lifespan in humans. None. Zero. The mouse findings have not translated to human longevity data. And there are good reasons to be concerned. They never will. We do have in humans a concerning picture of the side effects, and one that troubles me greatly is, is the gonadal toxicity. Rapamycin and its analogs. These drugs that are cousins of rapamycin or siblings, to make it even closer, they cause significant damage to reproductive function in both men and women because of the direct damage to the gonads, of course, the gonads being testes in men, ovaries in women. This isn't a minor inconvenience, but rather a reflection of some very serious harm that I think anyone should admit is fundamental to biological systems. In men, MTOR inhibitors cause decreased testosterone levels and disrupted spermatogenesis. At the same time, there's increased LH and fsh. Those are signals that come from the brain that are kind of surveying. The brain is the higher order manager of all the things that are happening in the body. And when it comes even to processes like producing testosterone, adequately producing sperm, the brain is monitoring this and it will send signals down to the testes accordingly. So if you find that the testosterone levels, for example, are low and then the brain signals going down to the testes are really high, that indicates that the testes are not responding properly to the signals from the brain. In other words, the testes are broken, if you will. They've disrupted this axis or this signaling axis. Clinical reports have documented that these drugs that there is an infertility in men associated with the use of these drugs. What's described as gonadal dysfunction. And these drugs are used in humans, especially in transplant patients. But even further, rapamycin induces seminiferous tubule dystrophy and spermatogenesis blockade. We're talking about testicular atrophy and damage to the Fundamental machinery of sperm production, not only producing it, but even getting it out. Those tubules, those little tubes that would be carrying it out are all breaking down. Of course, women are not spared these effects in their own way. Studies have documented high incidence of ovarian cysts in women receiving MTOR inhibitors after transplantation. And by that I mean tissue transplants. When they're on these rapamycin like drugs. Female kidney transplant patients that are on these drugs have developed amenorrhea, meaning a cessation of menstrual cycles and the drug stops normal ovarian function. Now some will argue that these effects may be reversible after stopping the drug. That is partially true from what we can tell based on the best available data. But think about what we are being asked to accept here. Take a drug that damages your gonads potentially beyond repair. It disrupts your sex hormone production, it impairs your fertility and you do it all on the hope that it might extend your lifespan. Based on some studies in mice, that to me is a terrible trade off. Especially when we don't have, when we, when we have other approaches that a person can consider to leverage these same pathways, I would say in a more optimal way to. Now I'm not declaring that rapamycin research is invaluable for understanding MTOR biology when it comes to specifically wanting to understand MTOR leveraging and manipulation, rapamycin is as good as it gets. But I am saying that the causal adoption or looking at rapamycin as something that's causing an increased or enhanced longevity by these enthusiasts and influencers biohackers. It's concerns me we're experimenting on humans with a drug that has known serious side effects and unproven longevity benefits in humans.
